Inactive Instrument
Mabvax Therapeutics Holdings Inc Stock Nasdaq
Stocks
US55414P7024
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 1.11M 956K 899K 821K 1.54M 105M 1.54M 10.62M 4.12M 53.8M 4.17M 4.08M 173M | P/E 2016 |
-0.93x | P/E 2017 | -0.25x |
|---|---|---|---|---|---|
| Enterprise Value | 3.59M 3.09M 2.91M 2.66M 4.97M 339M 4.98M 34.36M 13.33M 174M 13.49M 13.19M 561M | EV / Sales 2016 |
147x | EV / Sales 2017 | - |
| Free-Float |
92.02% | Yield 2016 * |
-
| Yield 2017 | - |
| 1 day | -11.76% |
| Manager | Title | Age | Since |
|---|---|---|---|
John Hansen
CEO | Chief Executive Officer | 74 | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -11.76% | +91.67% | - | - | 213K | |
| -1.79% | -3.82% | +38.74% | +91.90% | 69.02B | |
| -2.06% | -1.52% | +46.40% | +86.87% | 66.32B | |
| -0.31% | +6.54% | -11.39% | +378.92% | 27.66B | |
| +0.86% | +1.65% | +0.25% | -14.95% | 25.84B | |
| -3.00% | -2.61% | +34.45% | +11.39% | 26.54B | |
| -1.46% | -0.09% | +24.64% | -18.36% | 20.4B | |
| -2.96% | -16.03% | +213.13% | +375.00% | 17.63B | |
| -1.49% | -6.69% | -4.69% | +539.74% | 15.15B | |
| -0.20% | +8.37% | +57.87% | +164.98% | 14.65B | |
| Average | -2.38% | -0.66% | +44.37% | +179.50% | 31.47B | |
| Weighted average by Cap. | -1.50% | -0.45% | +40.23% | +138.88% |
| 2016 | 2017 | |
|---|---|---|
| Net sales | 148K 127K 120K 109K 205K 13.98M 205K 1.42M 550K 7.17M 556K 544K 23.1M | - |
| Net income | -17.66M -15.2M -14.3M -13.06M -24.43M -1.67B -24.5M -169M -65.56M -856M -66.32M -64.87M -2.76B | -19.02M -16.37M -15.4M -14.07M -26.32M -1.8B -26.39M -182M -70.61M -921M -71.42M -69.87M -2.97B |
| Net Debt | 470K 405K 381K 348K 650K 44.39M 652K 4.5M 1.75M 22.77M 1.77M 1.73M 73.36M | 2.48M 2.14M 2.01M 1.84M 3.43M 234M 3.44M 23.74M 9.21M 120M 9.32M 9.11M 387M |
Employees
-
